ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · IEX Real-Time Price · USD
3.910
+0.030 (0.77%)
At close: Jul 19, 2024, 4:00 PM
3.870
-0.040 (-1.02%)
Pre-market: Jul 22, 2024, 8:43 AM EDT
ZyVersa Therapeutics Employees
ZyVersa Therapeutics had 7 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$15,075,563
Market Cap
3.26M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7 | 0 | - |
Dec 31, 2022 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Xylo Technologies | 84 |
Aditxt | 47 |
Aptevo Therapeutics | 40 |
Healthcare Triangle | 31 |
Ensysce Biosciences | 7 |
CNS Pharmaceuticals | 5 |
Qualigen Therapeutics | 4 |
60 Degrees Pharmaceuticals | 3 |
ZVSA News
- 3 days ago - ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model - GlobeNewsWire
- 13 days ago - ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. - GlobeNewsWire
- 2 months ago - ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention - GlobeNewsWire
- 3 months ago - ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease - GlobeNewsWire
- 3 months ago - ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes - GlobeNewsWire
- 4 months ago - ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease - GlobeNewsWire